

Table 3. Overall survival. Results of pairwise comparisons with sunitinib (all risk groups combined)

Intervention	RCT number (name)	Risk of Bias*	Overall survival HR [95% CI]	Clinically relevant in favour of
Lenvantinib + Pembrolizumab	NCT02811861a (CLEAR)	High (D3)	0.66 [0.49, 0.88]	Lenvantinib + Pembrolizumab
Nivolumab + Ipilimumab	NCT02231749 (Checkmate 214)	Low	0.69 [0.59, 0.81]	Nivolumab + Ipilimumab
Pembrolizumab + Axitinib	NCT02853331 (KEYNOTE-426)	Low	0.73 [0.60, 0.88]	Pembrolizumab + Axitinib
Nivolumab + Cabozantinib	NCT03141177 (CHECKMATE 9ER)	High (D3, 5)	0.60 [0.44, 0.82]	Nivolumab + Cabozantinib
Cabozantinib	NCT02761057	Some concerns (D5)	0.84 [0.47, 1.51]	-
Pazopanib	NCT00720941 (COMPARZ)	Low	0.92 [0.79, 1.07]	-
Nintedanib	NCT01024920	Some concerns (D5)	0.92 [0.54, 1.56]	-
Temsirolimus	NCT00979966	High (D1, 2, 3, 5)	0.98 [0.31, 3.09]	-
Atezolizumab + Bevacizumab	NCT01984242b (IMmotion150)	Some concerns (D5)	1.30 [0.80, 2.12]	sunitinib
	NCT02420821	Low	0.91 [0.76, 1.08]	-
Atezolizumab	NCT01984242a	Some concerns (D5)	1.06 [0.65, 1.73]	-
Everolimus	NCT01108445 (ASPEN)	Some concerns (D5)	1.12 [0.48, 2.60]	-
Lenvantinib + Everolimus	NCT02811861b (CLEAR)	High (D3)	1.15 [0.88, 1.50]	-

* D1 Bias arising from the randomization process

D2 Bias due to deviations from intended intervention

D3 Bias due to missing outcome data

D4 Bias in measurement of the outcome

D5 Bias in selection of the reported result